C10orf105

Summary

C10orf105 (chromosome 10 open reading frame 105, HGNC:20304) is a protein-coding gene on chromosome 10q22.1, encoding Uncharacterized protein C10orf105 (Q8TEF2).

Predicted to be located in membrane.

Source: NCBI Gene 414152 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 580 total — 32 pathogenic, 33 likely-pathogenic
• Phenotypes (HPO): 2
• MANE Select transcript: NM_001164375

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20304
Approved symbol	C10orf105
Name	chromosome 10 open reading frame 105
Location	10q22.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ00245
Ensembl gene	ENSG00000214688
Ensembl biotype	protein_coding
Entrez	414152

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000398786, ENST00000441508, ENST00000941870

RefSeq mRNA: 2 — MANE Select: NM_001164375 NM_001164375, NM_001168390

CCDS: CCDS44430

Canonical transcript exons

ENST00000441508 — 2 exons

Exon	Start	End
ENSE00001645037	71719627	71719778
ENSE00001652599	71711701	71716342

Expression profiles

Bgee: expression breadth ubiquitous, 107 present calls, max score 80.83.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.3650 / max 63.8813, expressed in 96 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
109882	0.1562	63
109880	0.0823	48
109884	0.0425	21
109883	0.0288	15
109881	0.0240	16
109885	0.0160	8
109886	0.0153	6

Top tissues by expression

123 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
quadriceps femoris	UBERON:0001377	80.83	gold quality
blood	UBERON:0000178	78.82	gold quality
cerebellar vermis	UBERON:0004720	77.34	gold quality
hypothalamus	UBERON:0001898	76.81	gold quality
substantia nigra	UBERON:0002038	76.56	gold quality
granulocyte	CL:0000094	74.19	gold quality
monocyte	CL:0000576	72.55	gold quality
leukocyte	CL:0000738	72.54	gold quality
amygdala	UBERON:0001876	71.85	gold quality
temporal lobe	UBERON:0001871	71.73	gold quality
nucleus accumbens	UBERON:0001882	70.84	gold quality
caudate nucleus	UBERON:0001873	70.69	gold quality
Ammon’s horn	UBERON:0001954	69.65	gold quality
spleen	UBERON:0002106	66.18	gold quality
spinal cord	UBERON:0002240	65.20	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	65.12	gold quality
ventricular zone	UBERON:0003053	61.49	gold quality
putamen	UBERON:0001874	60.35	gold quality
thymus	UBERON:0002370	59.91	silver quality
anterior cingulate cortex	UBERON:0009835	59.27	gold quality
bone marrow cell	CL:0002092	58.75	gold quality
Brodmann (1909) area 9	UBERON:0013540	58.52	gold quality
lymph node	UBERON:0000029	58.49	gold quality
brain	UBERON:0000955	58.26	gold quality
vermiform appendix	UBERON:0001154	58.22	gold quality
cerebral cortex	UBERON:0000956	57.23	gold quality
bone marrow	UBERON:0002371	56.54	silver quality
right lung	UBERON:0002167	56.49	gold quality
right frontal lobe	UBERON:0002810	56.47	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	55.89	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.09

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

142 targeting C10orf105, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-6748-5P	100.00	65.81	1057
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-12121	99.99	66.64	255
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-345-3P	99.89	70.23	1421
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-182-5P	99.87	74.03	2589
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-4728-5P	99.85	69.39	4718

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Gm17455	ENSMUSG00000090439
rattus_norvegicus	Gm17455	ENSRNOG00000074800

Protein

Protein identifiers

Uncharacterized protein C10orf105 — Q8TEF2 (reviewed: Q8TEF2)

All UniProt accessions (1): Q8TEF2

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Membrane.

RefSeq proteins (2): NP_001157847, NP_001161862 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR039954	DUF5527	Family

Pfam: PF17665

UniProt features (5 total): chain 1, transmembrane region 1, region of interest 1, compositionally biased region 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TEF2-F1	63.46	0.13

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 21 (showing top): MIR4319, MIR4441, MIR6764_5P, MIR486_3P, MIR4270, MIR5193, MIR6754_5P, MIR1266_5P, MIR4518, MIR3922_5P, MIR7976, MIR4254, MIR3162_5P, MIR6827_5P, MIR4764_5P

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (1): membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	1

Protein interactions and networks

STRING

52 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
C10orf105	EGFL8	Q99944	582
C10orf105	RNF39	Q9H2S5	578
C10orf105	PPT2	Q9UMR5	514
C10orf105	VSIG8	P0DPA2	419
C10orf105	CDH23	Q9H251	400
C10orf105	FRMD4B	Q9Y2L6	323
C10orf105	PRDM16	Q9HAZ2	305
C10orf105	PLAAT4	Q9UL19	248
C10orf105	PROX2	Q3B8N5	230
C10orf105	ZNF714	Q96N38	223
C10orf105	ERICH1	Q86X53	220
C10orf105	ADARB2	Q9NS39	220
C10orf105	TMEM205	Q6UW68	202
C10orf105	STK32C	Q86UX6	200
C10orf105	TOMM40L	Q969M1	188

IntAct

0 interactions, top by confidence:

BioGRID (1): C10orf105 (Negative Genetic)

ESM2 similar proteins: A0A1B0GU29, A6NLX4, A6QNY1, A9CBA0, B7ZWI3, O14669, O88472, P14784, P16297, P25918, P26896, Q0VFL4, Q13651, Q32M26, Q38J84, Q38J85, Q3SYS8, Q58CT8, Q5BK39, Q5EAA5, Q5HZE8, Q5NCP0, Q5RCL0, Q64322, Q68DV7, Q6AXS2, Q6AXU5, Q6NUJ2, Q6UWV7, Q86UW2, Q8BHB3, Q8BLR5, Q8BSU2, Q8C353, Q8C708, Q8K1T1, Q8MII8, Q8N6P7, Q8NET5, Q8R182

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

580 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	32
Likely pathogenic	33
Uncertain significance	200
Likely benign	238
Benign	25

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1068856	NM_022124.6(CDH23):c.3457del (p.His1153fs)	Pathogenic
1071393	NC_000010.10:g.(?73199579)(73501688_?)del	Pathogenic
1073637	NM_022124.6(CDH23):c.3655C>T (p.Arg1219Ter)	Pathogenic
1076540	NM_022124.6(CDH23):c.3651del (p.Leu1218fs)	Pathogenic
1185587	NM_022124.6(CDH23):c.3353del (p.Gly1118fs)	Pathogenic
1378730	NM_022124.6(CDH23):c.3375del (p.Ala1126fs)	Pathogenic
1458297	NM_022124.6(CDH23):c.3713_3714del (p.Ser1238fs)	Pathogenic
1459529	NC_000010.10:g.(?73381150)(73553170_?)del	Pathogenic
1687244	NM_022124.6(CDH23):c.3431-1G>A	Pathogenic
179348	NM_022124.5(CDH23):c.(?3716)(4146_?)del	Pathogenic
2012237	NM_022124.6(CDH23):c.3762del (p.Lys1255fs)	Pathogenic
2136882	NM_022124.6(CDH23):c.3862C>T (p.Gln1288Ter)	Pathogenic
2763587	NM_022124.6(CDH23):c.3541_3559del (p.Tyr1181fs)	Pathogenic
2819985	NM_022124.6(CDH23):c.3321T>A (p.Tyr1107Ter)	Pathogenic
2834492	NM_022124.6(CDH23):c.3950dup (p.Tyr1318fs)	Pathogenic
2851838	NM_022124.6(CDH23):c.3413G>A (p.Trp1138Ter)	Pathogenic
3245004	NC_000010.10:g.(?73483792)(73490371_?)del	Pathogenic
3245009	NC_000010.10:g.(?73494902)(73501606_?)del	Pathogenic
3250301	NM_022124.6(CDH23):c.3715+2T>A	Pathogenic
3601266	NM_022124.6(CDH23):c.3715+1G>C	Pathogenic
3601277	NM_022124.6(CDH23):c.3801del (p.Thr1267_Val1268insTer)	Pathogenic
3632396	NM_022124.6(CDH23):c.4124del (p.Gly1375fs)	Pathogenic
3642098	NM_022124.6(CDH23):c.3322G>T (p.Glu1108Ter)	Pathogenic
4055753	NM_022124.6(CDH23):c.3367C>T (p.Gln1123Ter)	Pathogenic
45920	NM_022124.6(CDH23):c.3481C>T (p.Arg1161Ter)	Pathogenic
45926	NM_022124.6(CDH23):c.3628C>T (p.Gln1210Ter)	Pathogenic
4921	NM_022124.6(CDH23):c.3880C>T (p.Gln1294Ter)	Pathogenic
521399	NM_022124.6(CDH23):c.3241C>T (p.Arg1081Ter)	Pathogenic
560433	NM_022124.6(CDH23):c.3428dup (p.His1143fs)	Pathogenic
595857	NM_022124.6(CDH23):c.3221-2A>G	Pathogenic

SpliceAI

1963 predictions. Top by Δscore:

Variant	Effect	Δscore
10:71712654:A:AG	acceptor_gain	1.0000
10:71712655:A:G	acceptor_gain	1.0000
10:71712660:CACA:C	acceptor_loss	1.0000
10:71712662:CAG:C	acceptor_loss	1.0000
10:71712663:A:AG	acceptor_gain	1.0000
10:71712663:AG:A	acceptor_loss	1.0000
10:71712664:G:GA	acceptor_gain	1.0000
10:71712664:GA:G	acceptor_gain	1.0000
10:71712664:GAC:G	acceptor_gain	1.0000
10:71712664:GACA:G	acceptor_gain	1.0000
10:71712664:GACAA:G	acceptor_gain	1.0000
10:71724102:CATGG:C	donor_loss	1.0000
10:71724104:TGG:T	donor_loss	1.0000
10:71724105:GGTA:G	donor_loss	1.0000
10:71724106:G:GG	donor_gain	1.0000
10:71724106:GT:G	donor_loss	1.0000
10:71724107:T:TC	donor_loss	1.0000
10:71725519:GG:G	donor_gain	1.0000
10:71725520:GG:G	donor_gain	1.0000
10:71730468:GGT:G	acceptor_gain	1.0000
10:71730581:TCC:T	donor_gain	1.0000
10:71731753:T:TA	acceptor_gain	1.0000
10:71731754:G:A	acceptor_gain	1.0000
10:71732373:ACGGT:A	donor_loss	1.0000
10:71732374:CGGTG:C	donor_loss	1.0000
10:71732376:G:GC	donor_loss	1.0000
10:71732376:G:GG	donor_gain	1.0000
10:71732377:T:A	donor_loss	1.0000
10:71734625:A:AG	acceptor_gain	1.0000
10:71712656:C:G	acceptor_gain	0.9900

AlphaMissense

861 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:71716184:A:G	C52R	0.954
10:71716065:C:A	K91N	0.936
10:71716065:C:G	K91N	0.936
10:71716208:A:G	C44R	0.935
10:71716068:C:A	W90C	0.925
10:71716068:C:G	W90C	0.925
10:71716070:A:G	W90R	0.897
10:71716070:A:T	W90R	0.897
10:71716066:T:G	K91T	0.880
10:71716066:T:A	K91M	0.864
10:71716069:C:G	W90S	0.849
10:71716198:A:C	L47R	0.832
10:71716195:A:C	L48R	0.821
10:71716067:T:C	K91E	0.812
10:71716200:G:C	F46L	0.796
10:71716200:G:T	F46L	0.796
10:71716202:A:G	F46L	0.796
10:71716173:G:C	F55L	0.790
10:71716173:G:T	F55L	0.790
10:71716175:A:G	F55L	0.790
10:71716078:A:T	L87H	0.788
10:71716192:A:C	L49R	0.784
10:71716069:C:A	W90L	0.780
10:71715940:A:T	M133K	0.777
10:71715940:A:G	M133T	0.773
10:71716029:G:C	F103L	0.767
10:71716029:G:T	F103L	0.767
10:71716031:A:G	F103L	0.767
10:71716198:A:T	L47H	0.766
10:71716113:C:A	M75I	0.753

dbSNP variants (sampled 300 via entrez): RS1000050253 (10:71736681 C>T), RS1000125623 (10:71726383 G>A,C), RS1000205935 (10:71722370 C>T), RS1000319008 (10:71723584 A>G,T), RS1000350229 (10:71723738 C>T), RS1000430346 (10:71738157 G>C), RS1000546189 (10:71739563 G>A,C), RS1000651671 (10:71735574 G>A,T), RS1000653855 (10:71724747 T>C), RS1000686216 (10:71726877 C>G), RS1001009449 (10:71714182 A>G), RS1001204472 (10:71721832 G>A), RS1001232752 (10:71728167 C>G), RS1001256821 (10:71722109 A>G), RS1001513019 (10:71716753 C>T)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:601067, MIM:617540, MIM:601386, MIM:128600, MIM:220290, MIM:607197, MIM:276900, MIM:120970, MIM:500004, MIM:156000

GenCC curated gene-disease

Mondo (15): Usher syndrome type 1D (MONDO:0010984), Usher syndrome type 1 (MONDO:0010168), pituitary adenoma 5, multiple types (MONDO:0054601), autosomal recessive nonsyndromic hearing loss 12 (MONDO:0011067), ear malformation (MONDO:0007500), hearing loss, autosomal recessive (MONDO:0019588), Usher syndrome (MONDO:0019501), inherited retinal dystrophy (MONDO:0019118), cone-rod dystrophy (MONDO:0015993), optic atrophy (MONDO:0003608), hearing loss disorder (MONDO:0005365), retinitis pigmentosa-deafness syndrome (MONDO:0010775), Meniere disease (MONDO:0007972), intellectual disability (MONDO:0001071), vitreoretinal degeneration (MONDO:0020248)

Orphanet (10): Usher syndrome type 1 (Orphanet:231169), Usher syndrome (Orphanet:886), Rare autosomal recessive non-syndromic sensorineural deafness type DFNB (Orphanet:90636), Rare autosomal dominant non-syndromic sensorineural deafness type DFNA (Orphanet:90635), OBSOLETE: Inherited retinal disorder (Orphanet:71862), Rare genetic deafness (Orphanet:96210), Cone rod dystrophy (Orphanet:1872), NON RARE IN EUROPE: Menière disease (Orphanet:45360), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658), OBSOLETE: Vitreoretinal degeneration (Orphanet:98670)

HPO phenotypes

2 total (2 of 2 shown, HPO-id order):

HPO	Term
HP:0000556	Retinal dystrophy
HP:0007964	Degenerative vitreoretinopathy

GWAS associations

0 associations (top):

MeSH disease descriptors (9)

Descriptor	Name	Tree numbers
D000071700	Cone-Rod Dystrophies	C11.270.152; C11.768.585.658.250; C16.320.290.152
D034381	Hearing Loss	C09.218.458.341; C10.597.751.418.341; C23.888.592.763.393.341
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D008575	Meniere Disease	C09.218.568.217.500
D009896	Optic Atrophy	C10.292.700.225; C11.640.451
D058499	Retinal Dystrophies	C11.768.585.658
D052245	Usher Syndromes	C09.218.458.341.186.500.500; C09.218.458.341.887.886; C10.597.751.418.341.186.500.500; C10.597.751.418.341.887.886; C10.597.751.941.162.625.500; C11.768.585.658.500.813; C11.966.075.375.500; C16.131.077.299.500; C16.320.290.684.500; C23.888.592.763.393.341.887.886
C564609	Deafness, Autosomal Recessive (supp.)
C563327	Deafness, Autosomal Recessive 12 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

9 total (human), top 9 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
triphenyl phosphate	affects expression	1
ethyl-p-hydroxybenzoate	decreases expression	1
bisphenol S	decreases methylation	1
Resveratrol	affects cotreatment, decreases expression	1
Benzo(a)pyrene	affects methylation	1
Copper	decreases expression, affects cotreatment	1
Valproic Acid	increases methylation	1
Cadmium Chloride	decreases expression	1
Permethrin	decreases expression	1

Clinical trials (associated diseases)

298 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00205881	PHASE4	COMPLETED	Bilateral Benefit in Adult Users of the HiRes 90K Bionic Ear System
NCT00331539	PHASE4	UNKNOWN	Relationship Between Auto NRT and Behavioural T & C Levels With the Nucleus Freedom Cochlear Implant
NCT00424307	PHASE4	UNKNOWN	Bilateral Cochlear Implant Benefit in Young Children
NCT00765635	PHASE4	COMPLETED	Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal
NCT03321006	PHASE4	COMPLETED	Treating Hearing Loss to Improve Mood and Cognition in Older Adults
NCT07290530	PHASE3	NOT_YET_RECRUITING	24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
NCT04224207	PHASE3	COMPLETED	Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton’s Jelly Derived Mesenchymal Stem Cells
NCT07082855	PHASE3	NOT_YET_RECRUITING	A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa
NCT01499901	PHASE3	WITHDRAWN	Comparison of the Bilateral Sequential and Simultaneous Cochlear Implantation in the Deaf Children
NCT02561091	PHASE3	COMPLETED	AM-111 in the Treatment of Acute Inner Ear Hearing Loss
NCT03331627	PHASE3	COMPLETED	Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL
NCT05532657	PHASE3	ACTIVE_NOT_RECRUITING	ACHIEVE Brain Health Follow-Up Study
NCT02065011	PHASE2	ACTIVE_NOT_RECRUITING	A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B
NCT03763227	PHASE2	COMPLETED	Intravitreal Ranibizumab (Lucentis®) in the Treatment of Non-leaking Macular Cysts in Retinal Dystrophy
NCT04068207	PHASE2	COMPLETED	Minocycline Treatment in Retinitis Pigmentosa
NCT04945772	PHASE2	COMPLETED	Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
NCT01773278	PHASE2	RECRUITING	Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)
NCT00013455	PHASE2	COMPLETED	Quantifying Auditory Perceptual Learning Following Hearing Aid Fitting
NCT00323427	PHASE2	COMPLETED	Clinical Trial of the Living Well With Hearing Loss Workshop
NCT00552786	PHASE2	COMPLETED	Antioxidation Medication for Noise-induced Hearing Loss
NCT00802425	PHASE2	COMPLETED	Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss
NCT01139281	PHASE2	COMPLETED	The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans
NCT01451853	PHASE2	UNKNOWN	SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
NCT01588925	PHASE2	COMPLETED	Hearing Preservation Using Dexamethasone and Hyaluronic Acid for Cochlear Implantation
NCT02832128	PHASE2	COMPLETED	Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire)
NCT04915183	PHASE2	RECRUITING	Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
NCT05258773	PHASE2	COMPLETED	Evaluation of the Presence of SENS-401 in the Perilymph
NCT06340633	PHASE2	RECRUITING	SPI-1005 in Adults Receiving Cochlear Implant
NCT05902962	PHASE1	COMPLETED	SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects
NCT06319872	PHASE1	RECRUITING	The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
NCT06455826	PHASE1	COMPLETED	MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
NCT01064505	PHASE1	COMPLETED	Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
NCT05147701	PHASE1	RECRUITING	Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION
NCT00582946	PHASE1	COMPLETED	Wide-Bandwidth Open Canal Hearing Aid For Better Multitalker Speech Understanding
NCT00584155	PHASE1	WITHDRAWN	Protection From Cisplatin Ototoxicity by Lactated Ringers
NCT01206829	PHASE1	UNKNOWN	Hearing Impairment, Cognitive Therapy and Coping
NCT01256229	PHASE1	COMPLETED	Outcomes In Children With Developmental Delay And Deafness
NCT01343394	PHASE1	WITHDRAWN	Safety of Autologous Human Umbilical Cord Blood Mononuclear Fraction to Treat Acquired Hearing Loss in Children
NCT01452607	PHASE1	COMPLETED	Study to Evaluate the Safety and Pharmacokinetics of SPI-1005
NCT02259595	PHASE1	COMPLETED	Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC